NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch  «  1  2  3  4  5  » 
found files: 574
China Sky One Medical,Inc. »13/11/2007 [Company watch]
China Sky One Medical Reports Third Quarter 2007 Financial Results

3Q07 Revenue Up 148% to $16.8 Million ---- 3Q07 Net Income Up 195% to $5.4 Million HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced financial results for the three month and nine month periods ending September 30, 2007....   more»

Beijing Med-Pharm »14/11/2007 [Company watch]
Beijing Med-Pharm joins NASDAQ Biotechnology Index

Beijing Med-Pharm Corp. said it will be added to the NASDAQ Biotechnology Index on Nov. 19. Based in Plymouth Meeting, Pa., Beijing Med-Pharm (NASDAQ:BJGP) helps pharmaceutical and biotechnology companies get their products approved and sold in China. Its services include pre-market entry analysis, clinical trial management, product registration, market research, and pharmaceutical marketing and distribution....   more»

Pfizer »09/12/2007 [Company watch]
Pfizer looks to expand R&D presence in Asia

Pfizer Inc, the world's biggest drug maker, wants to expand its research and development activities in Asia, targeting China, India, Japan, and South Korea, an executive said on Friday. Pfizer, who makes blockbuster anti-cholesterol drug Lipitor and the erectile dysfunction drug Viagra, opened a research centre in Shanghai in 2005 and aims to expand clinical research activities globally, with nearly 80 studies ongoing....   more»

Sanofi-Aventis »29/11/2007 [Company watch]
Flu vaccine plant in Shenzhen biggest drug JV in China

The flu vaccine plant to be built in Shenzhen, agreed in a deal signed Monday between China and France's Sanofi-Aventis Group, will be the largest investment ever by a foreign drug maker in China. The 700-million-yuan (95.5-million U.S. dollars) plant will be built at the National Biological Industrial Base in Shenzhen's Longgang Grand Industrial Zone. The factory, to be run by Sanofi-Pasteur, the vaccine division of Europe's largest pharmaceuticals company Sanofi-Aventis, is expected to commence in early 2008. It would produce 25 million doses annually once production begins in 2012. By then, Shenzhen is expected to become China's - even Asia's - biggest vaccine manufacturing base....   more»

Novartis »04/12/2007 [Company watch]
Beijing Med-Pharm Announces Exclusive Agreement to Market Enablex® in China

Beijing Med-Pharm Corporation (NASDAQ:BJGP) ("Beijing Med-Pharm" or the "Company"), one of ChinaÔÇÖs leading pharmaceutical companies, and Shanghai Novartis Trading Limited, a wholly owned subsidiary of Novartis AG (NYSE: NVS), one of the top five pharmaceutical companies in the world, today announced an exclusive agreement to register, market and distribute Enablex┬« (Darifenacin) in the People's Republic of China....   more»

Simcere Pharmaceutical Group »26/11/2007 [Company watch]
Simcere Acquires Nanjing Tung Chit

Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that it has acquired 100% of Master Luck Corporation Limited, which holds 85.7% of Nanjing Tung Chit Pharmaceutical Co., Ltd. ("Tung Chit"), for a total cash consideration of RMB32.6 million (US$4.4 million). Tung Chit is a fast-growing manufacturer and supplier of anti-cancer drugs in China. Its leading product is a nedaplatin injection, trademarked as Jiebaisu, a first-to-market platinum based chemotherapeutic drug approved for the treatment of a wide range of solid tumors, including head-and-neck cancer, small cell and non-small cell lung cancer and esophageal cancer. Since its launch, Jiebaisu has been used by a number of major Chinese hospitals, specializing in cancer treatment, in many provinces across China. According to the China Hospital Drug Information, Jiebaisu's share of the nedaplatin market in China was over 80 percent in 2006. Being a new generation, broad spectrum platinum based chemotherapeutic drug, nedaplatin is expected to have significant growth potential in China....   more»

Johnson & Johnson »20/11/2007 [Company watch]
Johnson & Johnson to Hold 70% of Xi'an-Janssen

Johnson & Johnson Ltd. (NYSE: JNJ), plans to buy more shares in Xi'an-Janssen Pharmaceutical Ltd. from the latter's Chinese shareholders, according to an insider from the pharmaceutical joint venture on November 20, 2007. The buyer is in negotiations with three Chinese shareholders to acquire a 17.2% stake in the joint venture on the base that the equity structure of the sellers would not change. The acquisition has been approved by China's Ministry of Commerce, said the insider. The deal might enlarge Johnson & Johnson's holding in Xi'an-Janssen to 70% from currently 52%. Johnson & Johnson (China) Investment has recently acquired 1.8% of Xi'an-Janssen for CNY 78 million from Shaanxi Hanjiang Pharmaceutical Group Co., Ltd. The other three Chinese shareholders are Shaanxi Pharmaceutical Industry Corporation with a 33.6% stake; China National Pharmaceutical Industry Corporation 5.76%; and China National Pharmaceutical Foreign Trade Corporation 3.84%. Xi'an-Janssen was jointly set up by Belgium-based Janssen Pharmaceutica NV of Johnson & Johnson and the four Chinese state-owned companies in October 1985....   more»

»06/12/2007 [Company watch]
Shanghai Pharma to sell 50% equity of Shanghai Huzhong

Shanghai Pharmaceutical (SHA:600849) announced recently that it will sell 50% of its wholly owned subsidiary Shanghai Huzhong Pharmaceutical for RMB 135 million via bidding. The sale will list on Shanghai United Assets and Equity Exchange from November 19 to December 17. Priority will be given to buyers with the following qualifications: a drug distribution enterprise with 85% of revenue from pharmaceutical distribution sales, a publicly held company, an enterprise with more than RMB 90 billion in 2006 revenue from its pharmaceutical distribution business. Shanghai Huzhong Pharmaceutical is a pharmaceutical distribution enterprise with business including western medicine, nutritional supplements, sanitation materials and dressings, and retail medical equipment. Revenue and net profit for 2006 reached RMB 989 million and RMB 13 million, respectively. Shanghai Pharmaceutical announced May 17 that it will establish an equally owned joint venture based on Huzhong Pharmaceutical with Japan Suzuken. The Japanese company is listed on the Tokyo, Nagoya, and Sapporo Exchanges and is the second largest drug distributor in Japan....   more»

China Aoxing Pharmaceutical Company, Inc. »26/11/2007 [Company watch]
China Aoxing Pharmaceutical Designated as a Key Manufacturer of Cancer Pain Drug by China SFDA

China Aoxing Pharmaceutical Company, Inc. , which has the largest manufacturing facility and product pipeline for highly regulated narcotic medicines and pain medication in China, today announced that the China State Food & Drug Administration (SFDA) granted the Company the designated manufacturer status to produce Tilidine Tablets and Capsules, a highly regulated narcotic drug, in order to address significant unmet medical needs in cancer pain management in China. Maybe a working partner?...   more»

GlaxoSmithKline »13/12/2007 [Company watch]
GSK says will spend $100m in China R&D

Hong Kong, Dec 13, 2007: British pharma giant GlaxoSmithKline (GSK) has said it will invest $100 million by 2008 end to start a neuroscience research center in Shanghai. According to a UK business paper the Chinese center will become an important base for GSK to develop global drug. GSKÔÇÖs Chairman of R&D, Moncef Slaoui told the paper that the Shanghai center will be a one stop shop doing research on all neurodegenerative diseases such as Alzheimer's, Parkinson's disease and multiple sclerosis. The paper quoted him as saying, "For us, China is not about outsourcing and cheap labor. We don't want to give them the crumbs. It's about different science. We will link our fate to their fate. Within five to ten years we will be moving from 'made in China' to discovered in China." Increasingly global pharma companies are looking at China and India both as ready market and a place to do high end research due to their huge population and young scientists and professionals. GSK zeroed in on China as it was looking at the next seedbed for future discoveries. Slaoui said, "qualitatively and numerically, China came out on top, especially in oncology and neurology.ÔÇŁ...   more»

MPI Research »23/12/2007 [Company watch]
MPI & China Medicilon announce JV

MPI Research and Shanghai Medicilon are pleased to announce a new joint venture to form Medicilon-MPI Preclinical Research (Shanghai) LLC. Located initially at the Zhangjiang Hi-Tech Park in Shanghai, China, the company will open a 50,000 ft(2) preclinical testing facility in the Chuansha Economic Park in early 2008. This new facility will meet the regulatory standards set forth by the US FDA and other regulatory agencies worldwide....   more»

»27/12/2007 [Company watch]
Three Steps to Boost Asymchem's Investment in China

Asymchem, one of China's leading CMO companies, announced today the Company's investment and expansion plans in China. Apart from new plants and R & D facility, the Company will also invest heavily in training and form strategic alliances in the near future....   more»

Wuxi Pharma Tech »28/12/2007 [Company watch]
WuXi PharmaTech Mourns the Tragic Loss of Its

China's premier provider of pharmaceutical R&D outsourcing services, sadly announced today one of its independent directors, Mr. Shawn Wang, Chief Financial Officer of Baidu, passed away in an accident during his vacation on December 27, 2007. Mr. Shawn Wang was appointed as an independent director on WuXi PharmaTech's Board of Directors in July, 2007 when the company was preparing its public listing on the New York Stock Exchange. During his brief tenure and as the Chairman of the Audit Committee, Shawn advised the company's management in particular areas of financial reporting, Sarbanes-Oxley Act compliance and investor relations. "We are all deeply saddened by the tragic and untimely loss of Shawn. He was not only a remarkable leader but also a very close personal friend of mine," said Dr. Ge Li, Chairman and Chief Executive Officier of WuXi PharmaTech. "We are honored and grateful for having known and worked with Shawn. I will miss him very much and my thoughts and prayers go out to Shawn's family."...   more»

Wuxi Pharma Tech
»24/12/2007 [Company watch]
WuXi PharmaTech announced the company's first Life Science and Chemistry Awards Ceremony

The WuXi PharmaTech Life Science and Chemistry Award was approved by the National Office of Science and Technology Awards in early 2007, aiming to stimulate life science and chemistry research and reward those who have had significant achievements in their respective research fields. Mr. Zhang Huaixi and Mr. Li Meng, both Vice Chairmans of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), Mr. Xu Guanhua, the former Minister of the Ministry of Science and Technology, Mr. Cheng Jinpei, the Vice Minister of the Ministry of Science and Technology, and Mr. Gao Huchen, the Vice Minister of the Ministry of Commerce attended the ceremony and presented the awards to 17 young professionals in honor of their outstanding achievements in life science and chemistry fields....   more»

Wuxi Pharma Tech »04/01/2008 [Company watch]
WuXi Pharma to acquire AppTec

WuXi PharmaTech, a provider of pharmaceutical R&D outsourcing services from China, has signed a definitive agreement to acquire US-based AppTec Laboratory Services, (AppTec)....   more»

Wuxi Pharma Tech »04/01/2008 [Company watch]
WuXi PharmaTech promotes Edward Hu to COO

China's WuXi PharmaTech, a provider of pharmaceutical R&D outsourcing services, has promoted Mr Edward Hu from Executive Vice President of Operations to Chief Operating Officer (COO). Mr Hu has joined WuXi PharmaTech in August 2007, prior to that he was a senior vice president and COO of Tanox, later acquired by Genentech. He also worked for Biogen Idec as a business-planning manager and for Merck as a senior financial analyst. "We are very happy to promote Ed to give him more responsibilities, as Ed has quickly demonstrated his leadership capabilities and ability to contribute to the company. Ed will be based in US to lead the integration of AppTec after the deal is closed," said Dr Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. Mr Hu received his MBA and MS in Chemistry from Carnegie Mellon University, Pittsburgh, Pennsylvania...   more»

»09/01/2008 [Company watch]
Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility

Quintiles Transnational Corp. today announced the expansion and consolidation of its Global Central Laboratories and Clinical Development Services (CDS) units in Beijing to accommodate their growing business in China....   more»

»14/01/2008 [Company watch]
Unigene Laboratories, to broaden the activities of its joint venture

Unigene Laboratories, Inc. (OTCBB: UGNE) announced plans to broaden the activities of its joint venture with the Shijiazhuang Pharmaceutical Group Co., Ltd ("SPG") and to expand the potential product line to be developed and marketed by the joint venture. Unigene and SPG plan to establish the SPG-Unigene Biotechnology Research Institute in China. The Institute will continue ongoing registration activities for Unigene's calcitonin products, develop biopharmaceutical manufacturing facilities compliant with U.S. current Good Manufacturing Practice guidelines, and establish and supervise the creation of a new pharmaceutical distribution network for joint venture products in China, all to take advantage of the world's largest osteoporosis market. Unigene will maintain its 45% ownership position in the joint venture. The combined capital investment commitment for the joint venture will remain at $15 million. Unigene's initial cash contribution to the joint venture will remain at $900,000, which will be paid by Unigene upon the satisfaction of certain conditions, while the majority, or possibly all, of its remaining contribution will be in the form of technology. "The creation of the Institute should allow for the addition of potential new revenue-generating products and programs to our joint venture distinct from calcitonin, thereby expanding our commercial opportunities in China," commented Dr. Warren Levy, President and CEO of Unigene. "The formation of the Institute will allow us to take advantage of the rapidly growing market potential for biotechnology products in China, to apply for government funds to support joint venture programs and to more fully utilize the additional resources available as a result of the acquisition of SPG by a private equity fund led by Legend Holdings and Goldman Sachs, which occurred in August of 2007."...   more»

Wuxi Pharma Tech »07/01/2008 [Company watch]
WuXi names temporary chairman of audit committee

WuXi PharmaTech, China's premier provider of pharmaceutical R&D outsourcing services, announced that Mr Cuong Viet Do will temporarily assume the role of the Chairman of the Audit Committee until a permanent successor is appointed. The chairman of the Audit Committee was previously held by Mr Shawn Wang who recently expired in an accident during his vacation...   more»

»11/01/2008 [Company watch]
Benda pharma gets GMP certification, expands operations

China-based Benda Pharmaceuticals announced that its Ebei plant received Good Manufacturing Practices (GMP) certification for new tablets product line. The GMP certification clears the tablets for mass production and sale. As part of the expansion plan Benda added five new production lines to its product mix with respective annual capacities of 40 million oral liquid vials, 230 million capsules, 758 million tablets, 500 tons of pills and 20 million bags of granules....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.